868 results about "Galactosucrose" patented technology

The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.

The invention encompasses the use of a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida in various methods and uses, wherein said lipolytic enzyme is capable of hydrolysing a glycolipid or a phospholipid or transferring an acyl group from a glycolipid or phospholipids to an acyl acceptor. Preferably, the lipolytic enzyme for use in these methods and uses comprises an amino acid sequence as shown in any one of SEQ ID NOs: 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence having at least 70% identity therewith or comprises a nucleotide sequence shown as SEQ ID NO: 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70% identity therewith. The present invention also relates to a lipolytic enzyme capable of hydrolysing at least a galactolipid or capable of transferring an acyl group from a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable from Streptomyces species and includes a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID NO: 4 or an amino acid sequence which has at least 60% identity thereto. The enzyme may be encoded by a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence show in SEQ ID NO: 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID NO: 3.